

[View this email in your browser](#)

Randomized Trial to Prevent Vascular Events in HIV

Trial Status

March 11, 2019

7555 participants are enrolled

22 participants are in screening

Randomization will be closed after March 24th. Please make **ALL** efforts to enroll participants by this date as there will be no exceptions after this time.



REPRIEVE Investigator's Meeting 2019
Seattle, WA

The REPRIEVE Investigator's Meeting during CROI was a huge success! The meeting included a keynote presentation by Udo Hoffman, MD, MPH and a surprise performance of an *original* REPRIEVE song written and performed by Carl Fichtenbaum, MD. THANK YOU to all who joined us. [Click here](#) to download the slides if you were not able to join. See below for more photos.





Q: A REPRIEVE (A5332) participant had a cardiac CT scan and calcium score for another research study. The total score was elevated and the participant was referred to a cardiologist who diagnosed coronary artery disease due to a calcified coronary lesion. A stress test was performed which was negative. The plan is for the patient to follow up with the cardiologist again soon. Is this a potential event I should submit for adjudication?

A: This incidental calcium score finding on this asymptomatic participant does not merit submission as a potential adjudicated event at this time. However, this may change if the cardiologist decides to do a catheterization or other revascularization procedure or if there are other findings on further evaluation.



EVERY site enrolling participants in REPRIEVE will be receiving a Certificate of Achievement (if you haven't already)! The REPRIEVE CCC is in the process of distributing the certificates so watch for yours in the mail. Make sure your REPRIEVE team and participants see it and understand what a great accomplishment they are all a part of.

We Need Your Help With the 2019 Participant

Newsletter!




Participant Newsletter

Vol. 3 | 2018

The REPRIEVE CCC publishes a participant newsletter each year with the goals of providing study updates and maintaining study engagement. Including the voice of REPRIEVE participants is essential.

REPRIEVE participants have shared that they appreciate reading about other REPRIEVE participants' outlooks on the trial.

Do you have a participant that would want to share why participating in REPRIEVE is important to him/her? If so, please email us at reprieve.news@fstf.org.



Be Prepared to Return ECG Machines

Once enrollment is complete the REPRIEVE CCC will be reaching out to sites to return their ECG machine. In anticipation of this [please do the following](#):

1. Make sure your site has transmitted all ECGs to IQVIA.
2. Confirm the original ECG tracings are available in participant files.

Expectations of sites prior to shipping:

- Sites are expected to pack the ECG machine and accessories in the original box including all accessories (cables and power cord).
- Sites are not expected to return unused electrodes or paper.
- Sites need to return the device to the equipment warehouse as per instructions that will be provided.

If your site will not be enrolling additional participants please email Emma Kileel, ekileel@mgh.harvard.edu, who can facilitate the return of your ECG machine.

Save the Date!

Tuesday, March 19th, 2019
1:00 – 2:00 PM ET

For the March Monthly Site Call!

Watch for the email announcement with more details.



REPRIEVE (A5332): Are you up to date?

For A5332 please use:

Protocol Version 4.0 dated 03/28/2018

V4.0 LOA #1 dated 05/16/2018

MOPS Version 4.0 dated 10/16/18

A5332 LPC for ACTG Sites Version 4.0 dated 03/22/2018

A5332 LPC for Non-ACTG Sites Version 4.0 dated 07/23/2018

These documents are on the [A5332 PSWP](#)

Mechanistic Substudy of REPRIEVE (A5333s): Are you up to date?

For A5333s please use

Protocol Version 4.0 dated 03/28/2018

MOPS Version 4.0 dated 04/10/2018

A5333s LPC Version 4.0 dated 03/23/2018

These documents are on the [A5333s PSWP](#)

**For future reference, all newsletters are
available on the [REPRIEVE Website](#).**

*We welcome ideas and suggestions for future newsletters. Please submit any
comments or suggestions to the REPRIEVE News team at reprieve.news@fstrf.org*



REPRIEVE Trial Clinical Coordinating Center

Massachusetts General Hospital

55 Fruit Street, 5LON 207

Boston, MA USA 02144

Our mailing address is:

reprieve.news@fstrf.org

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

This email was sent to <<Email Address>>
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)
Massachusetts General Hospital · 5 Longfellow Place · Boston, MA 02214 · USA

